2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

• Ruperto N,
• Quartier P,
• Wulffraat N,
• Woo P,
• Loy A,
• Mouy R,
• Bader-Meunier B,
• Prakken B,
• Noseda E,
• Rordorf C

Affiliations

Ruperto N

Quartier P

Wulffraat N

Woo P

Loy A

Mouy R

Bader-Meunier B

Prakken B

Noseda E

Rordorf C